The Online Investor
HI-Tech Pharmacal Co., Inc. (HITK)

Hi-Tech Pharmacal develops, manufactures and markets generic and branded prescription and over the counter (OTC) products. Co.'s generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. Co.'s Health Care Products division markets a line of OTC products for people with diabetes, including Diabetic Tussin®, DiabetiDerm®, Multi-betic®, Mag-Ox®, and DiabetiSweet®, and sells the Zostrix® brand of capsaicin products. Co.'s ECR Pharmaceuticals Co., Inc. subsidiary markets and distributes branded prescription pharmaceuticals that treat diseases including pain, cough/cold and allergies, and swimmer's ear.
Company Name: 
HI-Tech Pharmacal Co., Inc.
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree HITK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.50 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

HI-Tech Pharmacal Co., Inc. (HITK) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.